Linerixibat

Generic Name
Linerixibat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H38N2O7S
CAS Number
1345982-69-5
Unique Ingredient Identifier
386012Z45S
Background

GSK2330672 has been investigated for the treatment of Diabetes Mellitus, Type 2.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)

Conditions
Pruritus
First Posted Date
2022-07-07
Last Posted Date
2023-11-08
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT05448170

Food Effect Study of Linerixibat Tablets in Healthy Adult Participants

Phase 1
Completed
Conditions
Pruritus
Interventions
Drug: linerixibat
First Posted Date
2022-06-28
Last Posted Date
2022-11-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
23
Registration Number
NCT05435170
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

Phase 1
Completed
Conditions
Pruritus
Interventions
Drug: Linerixibat
First Posted Date
2022-05-26
Last Posted Date
2023-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
8
Registration Number
NCT05393076
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Phase 1
Completed
Conditions
Pruritus
Interventions
Drug: Obeticholic acid
Drug: Linerixibat
First Posted Date
2021-11-24
Last Posted Date
2022-11-08
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
52
Registration Number
NCT05133830
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Phase 3
Active, not recruiting
Conditions
Pruritus
Interventions
Drug: Linerixibat
Drug: Placebo
First Posted Date
2021-07-06
Last Posted Date
2024-07-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
238
Registration Number
NCT04950127
Locations
🇬🇧

GSK Investigational Site, Surrey, United Kingdom

Linerixibat Long-term Safety, and Tolerability Study

Phase 3
Recruiting
Conditions
Cholestasis
Interventions
Drug: Linerixibat
First Posted Date
2019-11-18
Last Posted Date
2024-11-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
305
Registration Number
NCT04167358
Locations
🇬🇧

GSK Investigational Site, Surrey, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy